

PEDIATRIC PHARMACOTHERAPY

A Monthly Newsletter for Health Care Professionals
Children's Medical Center at the University of Virginia

Volume 3 Number 1

January 1997

Two-Year Index for *Pediatric Pharmacotherapy*

The following index has been prepared from key terms used in *Pediatric Pharmacotherapy* over the past two years. The first column indicates volume and issue numbers with a symbol indicating the type of citation. In this index, L= literature review (abstract), M= main (feature) article, and F= FDA update. The second column provides month and year of publication.

A

Acetaminophen	2(7)M	7/96
Acetaminophen, renal effects	1(6)L	6/95
Aclometasone	2(1)M	1/96
Aclovate®	2(1)M	1/96
Acute pain, management	2(6)L	6/96
Adverse drug reactions, frequency in children	2(10)L	10/96
Adverse drug reactions, reporting	1(3)M	3/95
Adverse effects, causality	2(11)L	11/96
Albuterol	2(5)M	5/96
Amcinonide	2(1)M	1/96
Angiotensin-converting enzyme inhibitors	2(2)L	2/96
Antibiotics, allergies	1(12)L	12/95
Antibiotics, comparison of oral	2(4)L	4/96
Anticonvulsants, developments	2(11)L	11/96
Anticonvulsants, pharmacokinetics	Part I.	
	1(12)L	12/95
Anticonvulsants, pharmacokinetics	Part II.	
	2(1)L	1/96
Antihistamines	1(9)M	9/95
Antipyretics	2(7)M	7/96
Astemizole	1(9)M	9/95
Asthma, steroids	1(1)L	1/95
Asthma, therapy in adolescents	1(8)L	8/95
Atenolol, use in Marfan syndrome	1(5)L	5/95
Atropine	2(12)M	12/96
Attention deficit/hyperactivity disorder, therapy	1(12)M	12/95
Autism, medications	1(2)L	2/95

Azithromycin 2(2)M 2/96

B

Benadryl®	1(9)M	9/95
Benzalkonium chloride	2(9)M	9/96
Benzyl alcohol	2(9)M	9/96
Betamethasone	2(1)M	1/96
Biaxin®	2(2)M	2/96
Breastfeeding, effects of drugs on neonatal hepatic function	2(4)M	4/96
Breastfeeding, effects of drugs during	1(12)L	12/95
Brompheniramine	1(9)M	9/95
Bumetanide	1(10)M	10/95

C

Caffeine	1(3)L	3/95
Calcium chloride	2(12)M	12/96
Carbamazepine	2(11)M	11/96
Carbamazepine, cyclosporine interaction	1(6)L	6/96
Carbamazepine, drug interactions	2(10)L	10/96
Carbamazepine, Stevens-Johnson syndrome	1(6)L	6/96
Cardiovascular drugs, pharmacokinetics	1(1)L	1/95
Ceclor®	2(6)M	6/96
Cedax®	2(6)M	6/96
Cefaclor	2(6)M	6/96
Cefadroxil	2(6)M	6/96
Cefixime, therapy review	1(8)L	8/95
Cefixime	2(6)M	6/96
Cefpodoxime	2(6)M	6/96
Cefprozil	2(6)M	6/96
Ceftazidime	1(4)L	4/95
Ceftazidime, use in infants	2(2)L	2/96
Ceftibuten	2(6)M	6/96
Ceftin®	2(6)M	6/96

Cefuroxime axetil	2(6)M	6/96	Digoxin, drug interactions	1(4)L	4/95
Cefuroxime axetil, therapy review	2(7)L	7/96	Dilantin®	2(8)M	8/96
Cefzil®	2(6)M	6/96	Dilution of medications for neonates	1(8)L	8/95
Cephalexin	2(6)M	6/96	Dimetane®	1(9)M	9/95
Cephalosporins, review of oral	2(6)M	6/96	Diphenhydramine	1(9)M	9/95
Cephradine	2(6)M	6/96	Diprolene AF®	2(1)M	1/96
Children's Motrin®	2(7)M	7/96	Diprosone®	2(1)M	1/96
Chlorothiazide	1(10)M	10/95	Diuretics	1(10)M	10/95
Chlorpheniramine	1(9)M	9/95	Dornase alpha	1(1)L	1/95
Chlor-Trimeton®	1(9)M	9/95	Dornase alpha, cost-benefit analysis	1(6)L	6/95
Cisapride, drug interactions	2(11)L	11/96	Dornase alpha, update	2(3)L	3/96
Clarithromycin	2(2)M	2/96	Drug approval process, FDA	1(11)M	11/95
Claritin®	1(9)M	9/95	Drug-nutrient interactions	1(5)M	5/95
Clearance	1(7)M	7/95	Drug reactions, idiosyncratic	2(10)L	10/96
Clemastine	1(9)M	9/95	Duricef®	2(6)M	6/96
Clobetasol	2(1)M	1/96	Dyes and colorants, pharmaceutical	2(9)M	9/96
Clocortolone	2(1)M	1/96			
Cloderm®	2(1)M	1/96			
Clonazepam, pharmacokinetics	2(3)L	3/96			
Clonidine	1(12)M	12/95			
Compliance with medications	1(4)L	4/95	E		
Conscious sedation	2(3)L	3/96	Elocon®	2(1)M	1/96
Cordran®	2(1)M	1/96	EMLA, use with subcutaneous infusions	1(5)L	5/95
Cortaid®	2(1)M	1/96	Epilepsy, diagnosis and treatment	2(4)L	4/96
Corticosteroids, topical	2(1)M	1/96	Epinephrine	2(12)M	12/96
Cortizone®	2(1)M	1/96	Epoetin	1(3)L	3/95
Coumadin®	1(1)M	1/95	Erythromycin	2(2)M	2/96
Creatinine clearance, prediction	1(10)L	10/95	Ethanol	2(9)M	9/96
Crotamiton	1(8)M	8/95	Etoposide, pharmacokinetics and pharmacodynamics	1(9)L	9/95
Cutivate®	2(1)M	1/96	Excipients, pharmaceutical	2(9)M	9/96
Cyclic antidepressant toxicity	1(5)L	5/95			
Cyclocort®	2(1)M	1/96	F		
Cyclosporine	1(4)M	4/95	Famotidine	2(9)L	9/96
Cyclosporine, absorption	2(3)L	3/96	Famotidine, pharmacokinetics and pharmacodynamics	2(3)L	3/96
Cyclosporine, carbamazepine interaction	1(6)L	6/95	Flavorings, pharmaceutical	2(9)M	9/96
Cyclosporine, drug interactions	2(4)L	4/96	Florone®	2(1)M	1/96
Cyclosporine, norfloxacin interaction	1(11)L	11/95	Fluconazole, interaction with warfarin	2(5)L	5/96
Cystic fibrosis, drug metabolism	1(1)L	1/95	Fluconazole, pharmacokinetics	1(2)L	2/95
Cystic fibrosis, therapy of complications	1(11)L	11/95	Fluocinolone	2(1)M	1/96
Cystic fibrosis, tobramycin pharmacokinetics	2(5)L	5/96	Fluocinonide	2(1)M	1/96
Cytochrome P450 enzymes	1(7)L	7/95	Fluoxetine	2(10)M	10/96
			Flurandrenolide	2(1)M	1/96
D			Fluticasone	2(1)M	1/96
Decadron®	2(1)M	1/96	Fluvoxamine	2(10)M	10/96
Desonide	2(1)M	1/96	Food and Drug Administration, drug approval process	1(11)M	11/95
Desoximetasone	2(1)M	1/96	Furosemide	1(10)M	10/95
Dexamethasone	2(1)M	1/96			
Dextroamphetamine	1(12)M	12/95			
			G		
Diflorasone	2(1)M	1/96	G-CSF	1(1)L	1/95

G-CSF, binding to catheters 1(2)L 2/95
 Gentamicin, dosing in neonates 1(7)L 7/95
 Gentamicin, pharmacokinetics in children with cancer 2(1)L 1/96
 Gestational diabetes, management 2(7)L 7/96

H

Halcinonide 2(1)M 1/96
 Half-life 1(7)M 7/95
 Halobetasol 2(1)M 1/96
 Halog® 2(1)M 1/96
 Hismanal® 1(9)M 9/95
 HIV, therapy in children 1(6)L 6/95
 Hydrochlorothiazide 1(10)M10/95
 Hydrocortisone 2(1)M 1/96
 Hypertension, treatment 1(1)L 1/95

I

Ibuprofen, overdose 1(10)L10/95
 Ibuprofen, review 2(7)M 7/96
 Idiosyncratic drug reactions 2(10)L 10/96
 Imipenem/cilastatin 2(2)L 2/96
 Immune globulin, use in pediatric AIDS 1(5)L 5/95
 INR 1(1)M 1/95
 Isoniazid 1(2)L 2/95

J-K

Keflex® 2(6)M 6/96
 Kenalog® 2(1)M 1/96
 Kwell® 1(8)M 8/95

L

Lamotrigine 1(3)L 3/95
 Lamotrigine, update 1(12)L 12/95
 Lice, treatment 1(8)M 8/95
 Lidex® 2(1)M 1/96
 Lindane 1(8)M 8/95
 Lorabid® 2(6)M 6/96
 Loracarbef 2(6)M 6/96
 Loratadine 1(9)M 9/95
 Luvox® 2(10)M10/96

M

Macrolides, drug interactions 1(9)L 9/95
 Macrolides, review 2(2)M 2/96
 Malathion 1(8)M 8/95
 Maxiflor® 2(1)M 1/96
 Medication errors, prevention 1(1)L 1/95
 MedWatch 1(3)M 3/95
 MedWatch, data from 1(8)L 8/95
 Methemoglobinemia, drug-induced 2(8)L 8/96

Methotrexate, pharmacokinetics 1(4)L 4/95
 Methylphenidate 1(12)M12/95
 Metoclopramide 1(3)L 3/95
 Metolazone 1(10)M10/95
 Midazolam, clearance in children 2(2)L 2/96
 Midazolam, compatibility 1(12)L 12/95
 Midazolam, intranasal 2(5)L 5/96
 Midazolam, use in neonates 1(2)L 2/95
 Milk:Plasma ratio 2(4)M 4/96
 Mometasone 2(1)M 1/96
 Moricizine 1(12)L 12/95
 Morphine, use in neonates 1(1)L 1/95

N

Naloxone 2(12)M12/96
 New drug development 1(7)L 7/95
 Non-prescription medications 1(5)L 5/95
 Nonsteroidal anti-inflammatory drugs, renal effects 1(6)L 6/96
 Norfloxacin, cyclosporine interaction 1(11)L 11/95

O

Ondansetron, outpatient use 1(2)L 2/95
 Ondansetron, pharmacokinetics 1(11)L 11/95
 Opiates, respiratory depression 2(3)L 3/96
 Oral contraceptives 1(3)L 3/95

P

Pain management 2(3)L 3/96
 Pain, management of acute 2(6)L 6/96
 Parenteral nutrition 1(3)L 3/95
 Paroxetine 2(10)M10/96
 Paxil® 2(10)M10/96
 Pediatric pharmacology library 1(6)M 6/95
 Pemoline 1(12)M12/95
 Pemoline, liver failure 1(8)L 8/95
 Permethrin 1(8)M 8/95
 Pharmaceutical excipients 2(9)M 9/96
 Phenytoin 2(8)M 8/96
 Placebo response 2(11)L11/96
 Placental drug transfer, antipyrine model 2(1)L 1/96
 Placental drug transfer, mechanisms 1(4)L 4/95
 Poison Prevention 1(3)M 3/95
 “ “ 2(3)M 3/96
 Polyethylene glycol 2(9)M 9/96
 Preservatives, pharmaceutical 2(9)M 9/96
 Propylene glycol 2(9)M 9/96
 Prozac® 2(10)M10/96
 Psychiatric disorders, treatment 2(6)L 6/96
 Psychotropic use, predicting 2(9)L 9/96
 Propofol, use in intensive care 1(12)L 12/95

Pyrethrins 1(8)M 8/95

Q-R

Recent advances in pharmacology 1(2)L 2/95

Risperidone, toxicity 2(5)L 5/96

S

Salmeterol 1(1)F 1/95

Scabies, treatment 1(8)M 8/95

Scabies, treatment update 2(8)L 8/96

Seldane® 1(9)M 9/95

Selective serotonin reuptake inhibitors
2(10)M10/96

Serevent® 1(1)F 1/95

Sertraline 2(10)M10/96

Skin reactions, drug-induced 1(9)L 9/95

Smoking cessation 1(3)L 3/95

Sodium bicarbonate 2(12)M12/96

Solvents, pharmaceutical 2(9)M 9/96

Spirolactone 1(10)M10/95

Sufentanil, intranasal 2(5)L 5/96

Suprax® 2(6)M 6/96

Surfactant 2(3)L 3/96

Sweeteners, pharmaceutical 2(9)M 9/96

Synalar® 2(1)M 1/96

T

Tavist-D® 1(9)M 9/95

Tegretol® 2(11)M11/96

Temovate® 2(1)M 1/96

Terfenadine 1(9)M 9/95

Terfenadine, transfer into breastmilk
1(5)L 5/95

Theophylline, dosing equations 1(4)L 4/95

Theophylline, dosing guidelines 1(9)L 9/95

Theophylline, drug interactions 1(5)L 5/95

Therapeutic drug monitoring 1(7)M 7/95

Therapeutic equivalence 2(12)L12/96

Ticarcillin/clavulanic acid, dosing 1(9)L 9/95

Tobramycin, pharmacokinetics in cystic fibrosis
2(5)L 5/96

Topicort® 2(1)M 1/96

Triamcinolone 2(1)M 1/96

Tridesilon® 2(1)M 1/96

Tylenol® 2(7)M 7/96

U

Ultravate® 2(1)M 1/96

Uticort® 2(1)M 1/96

V

Vaccine Adverse Event Reporting System
(VAERS) 1(3)M 3/95

Vaccines, storage 1(6)M 6/96

Valisone® 2(1)M 1/96

Valproate, pharmacokinetics 1(12)L12/95

Vancomycin 1(2)M 2/95

Vancomycin-resistant enterococci 1(2)M 2/95

Vantin® 2(6)M 6/96

Varicella vaccine 1(7)F 7/95

Velosef® 2(6)M 6/96

Vitamin K 1(4)L 4/95

Volume of distribution 1(7)M 7/95

W

Warfarin 1(1)M 1/95

Warfarin, interaction with fluconazole
2(5)L 5/96

Westcort® 2(1)M 1/96

X-Z

Zidovudine, use in pregnancy 1(8)L 8/95

Zithromax® 2(2)M 2/96

Zolofit® 2(10)M10/96

A limited number of copies of back issues are available. If interested in obtaining a back issue, please contact Marcia Buck at the address listed below.

Contributing Editor: Marcia L. Buck, PharmD

Editorial Board: Robert J. Roberts, MD, PhD

Anne E. Hendrick, PharmD

Bernadette S. Belgado, PharmD

Production Manager: Sharon L. Estes

If you have comments or would like to be on our mailing list, please contact Marcia Buck by mail at Box 274-11, University of Virginia Medical Center, Charlottesville, VA 22908 or by phone (804) 982-0921, fax (804) 982-1682, or e-mail to mlb3u@virginia.edu.